Anupam Rama
Stock Analyst at JP Morgan
(4.41)
# 304
Out of 5,154 analysts
300
Total ratings
49.02%
Success rate
21.24%
Average return
Main Sectors:
Stocks Rated by Anupam Rama
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $36 → $37 | $20.07 | +84.35% | 19 | Mar 5, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiates: Overweight | $32 | $13.62 | +134.95% | 1 | Mar 3, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $177 → $176 | $128.13 | +37.36% | 21 | Feb 17, 2026 | |
| ZLAB Zai Lab | Maintains: Overweight | $46 → $39 | $19.54 | +99.59% | 13 | Feb 5, 2026 | |
| VERA Vera Therapeutics | Maintains: Overweight | $99 → $96 | $39.07 | +145.71% | 12 | Dec 19, 2025 | |
| COGT Cogent Biosciences | Maintains: Overweight | $65 → $67 | $37.08 | +80.69% | 9 | Dec 19, 2025 | |
| VOR Vor Biopharma | Maintains: Overweight | $43 → $40 | $15.12 | +164.55% | 2 | Dec 19, 2025 | |
| NUVL Nuvalent | Maintains: Overweight | $147 → $145 | $99.41 | +45.86% | 7 | Dec 19, 2025 | |
| NVAX Novavax | Maintains: Underweight | $7 → $6 | $9.98 | -39.88% | 1 | Nov 18, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Overweight | $17 → $20 | $13.71 | +45.88% | 7 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $32 | $21.55 | +48.49% | 6 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $13.54 | +25.55% | 1 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $33 | $22.07 | +49.52% | 11 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $27 | $21.20 | +27.36% | 5 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $77 | $65.36 | +17.81% | 12 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $19 | $14.34 | +32.50% | 14 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $11 | $6.75 | +62.96% | 9 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 → $24 | $24.86 | -3.46% | 8 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $79 | $33.19 | +138.02% | 11 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 | $8.07 | +36.31% | 12 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $37 | $44.83 | -17.47% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.20 | - | 1 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $24 | $16.71 | +43.63% | 17 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $80 | $55.41 | +44.38% | 12 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $117 | $21.25 | +450.59% | 3 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $44 | $27.24 | +61.53% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $40 | $46.16 | -13.34% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.30 | - | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.91 | - | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.68 | - | 3 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $5.16 | +151.94% | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 | $5.17 | +4,735.59% | 7 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.40 | - | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $58 | $60.41 | -3.99% | 1 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 → $12 | $13.57 | -11.57% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $29 → $37 | $9.55 | +287.43% | 6 | Oct 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $55 | $92.09 | -40.28% | 3 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $14 → $38 | $10.16 | +274.02% | 13 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $15.47 | +81.00% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $54 | $27.47 | +96.58% | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $0.17 | +26,717.64% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $14.86 | +81.70% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $133 → $137 | $320.66 | -57.28% | 9 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $48 | $6.81 | +604.85% | 5 | Jul 12, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.97 | +2,992.78% | 1 | Dec 4, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $62.82 | - | 2 | Nov 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.50 | - | 2 | Jul 21, 2017 |
Apellis Pharmaceuticals
Mar 5, 2026
Maintains: Overweight
Price Target: $36 → $37
Current: $20.07
Upside: +84.35%
AgomAb Therapeutics NV
Mar 3, 2026
Initiates: Overweight
Price Target: $32
Current: $13.62
Upside: +134.95%
Neurocrine Biosciences
Feb 17, 2026
Maintains: Overweight
Price Target: $177 → $176
Current: $128.13
Upside: +37.36%
Zai Lab
Feb 5, 2026
Maintains: Overweight
Price Target: $46 → $39
Current: $19.54
Upside: +99.59%
Vera Therapeutics
Dec 19, 2025
Maintains: Overweight
Price Target: $99 → $96
Current: $39.07
Upside: +145.71%
Cogent Biosciences
Dec 19, 2025
Maintains: Overweight
Price Target: $65 → $67
Current: $37.08
Upside: +80.69%
Vor Biopharma
Dec 19, 2025
Maintains: Overweight
Price Target: $43 → $40
Current: $15.12
Upside: +164.55%
Nuvalent
Dec 19, 2025
Maintains: Overweight
Price Target: $147 → $145
Current: $99.41
Upside: +45.86%
Novavax
Nov 18, 2025
Maintains: Underweight
Price Target: $7 → $6
Current: $9.98
Upside: -39.88%
ORIC Pharmaceuticals
Nov 18, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $13.71
Upside: +45.88%
Nov 18, 2025
Maintains: Overweight
Price Target: $29 → $32
Current: $21.55
Upside: +48.49%
Nov 14, 2025
Initiates: Overweight
Price Target: $17
Current: $13.54
Upside: +25.55%
Nov 12, 2025
Maintains: Overweight
Price Target: $40 → $33
Current: $22.07
Upside: +49.52%
Nov 7, 2025
Maintains: Overweight
Price Target: $26 → $27
Current: $21.20
Upside: +27.36%
Nov 7, 2025
Maintains: Overweight
Price Target: $76 → $77
Current: $65.36
Upside: +17.81%
Nov 6, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $14.34
Upside: +32.50%
Nov 5, 2025
Maintains: Overweight
Price Target: $13 → $11
Current: $6.75
Upside: +62.96%
Oct 24, 2025
Upgrades: Overweight
Price Target: $15 → $24
Current: $24.86
Upside: -3.46%
Oct 23, 2025
Maintains: Overweight
Price Target: $74 → $79
Current: $33.19
Upside: +138.02%
Oct 20, 2025
Upgrades: Neutral
Price Target: $11
Current: $8.07
Upside: +36.31%
Sep 29, 2025
Maintains: Overweight
Price Target: $27 → $37
Current: $44.83
Upside: -17.47%
Sep 16, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.20
Upside: -
Jul 29, 2025
Upgrades: Neutral
Price Target: $24
Current: $16.71
Upside: +43.63%
Jul 24, 2025
Maintains: Overweight
Price Target: $42 → $80
Current: $55.41
Upside: +44.38%
Mar 27, 2025
Maintains: Overweight
Price Target: $104 → $117
Current: $21.25
Upside: +450.59%
Feb 26, 2025
Maintains: Overweight
Price Target: $42 → $44
Current: $27.24
Upside: +61.53%
Nov 5, 2024
Maintains: Overweight
Price Target: $39 → $40
Current: $46.16
Upside: -13.34%
Sep 30, 2024
Initiates: Neutral
Price Target: n/a
Current: $2.30
Upside: -
May 15, 2024
Downgrades: Neutral
Price Target: n/a
Current: $10.91
Upside: -
Apr 22, 2024
Upgrades: Neutral
Price Target: n/a
Current: $4.68
Upside: -
Apr 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $5.16
Upside: +151.94%
Jul 13, 2022
Downgrades: Neutral
Price Target: $250
Current: $5.17
Upside: +4,735.59%
Mar 8, 2022
Downgrades: Neutral
Price Target: n/a
Current: $8.40
Upside: -
Dec 10, 2021
Initiates: Overweight
Price Target: $58
Current: $60.41
Upside: -3.99%
Nov 5, 2021
Upgrades: Neutral
Price Target: $7 → $12
Current: $13.57
Upside: -11.57%
Oct 25, 2021
Upgrades: Neutral
Price Target: $29 → $37
Current: $9.55
Upside: +287.43%
Oct 12, 2021
Upgrades: Overweight
Price Target: $55
Current: $92.09
Upside: -40.28%
Oct 11, 2021
Upgrades: Neutral
Price Target: $14 → $38
Current: $10.16
Upside: +274.02%
Aug 10, 2021
Initiates: Overweight
Price Target: $28
Current: $15.47
Upside: +81.00%
Mar 1, 2021
Downgrades: Neutral
Price Target: $54
Current: $27.47
Upside: +96.58%
Jan 11, 2021
Initiates: Overweight
Price Target: $45
Current: $0.17
Upside: +26,717.64%
Oct 12, 2020
Initiates: Overweight
Price Target: $27
Current: $14.86
Upside: +81.70%
May 7, 2020
Downgrades: Neutral
Price Target: $133 → $137
Current: $320.66
Upside: -57.28%
Jul 12, 2019
Downgrades: Neutral
Price Target: $29 → $48
Current: $6.81
Upside: +604.85%
Dec 4, 2017
Initiates: Overweight
Price Target: $30
Current: $0.97
Upside: +2,992.78%
Nov 16, 2017
Upgrades: Neutral
Price Target: n/a
Current: $62.82
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.50
Upside: -